Zydus Lifesciences shares gain momentum as Phase 3 EPICS-III trial data reveals superior biochemical response rates for saroglitazar in U.S. patients suffering from primary biliary cholangitis.
Zydus Lifesciences' saroglitazar has demonstrated significant clinical efficacy in the Phase 3 EPICS-III trial for treating primary biliary cholangitis (PBC). The data highlights a robust biochemical response, particularly in the U.S. patient subgroup, which strengthens the drug's potential market positioning and regulatory outlook.
The trial showed a numerically higher biochemical response in patients with PBC, with a more pronounced treatment difference in the U.S. subgroup (60.7%) compared to the non-U.S. subgroup (41.6%).
Zydus Lifesciences announced positive Phase 3 EPICS-III trial data for saroglitazar, demonstrating significant biochemical improvements in patients with primary biliary cholangitis. The U.S. subgroup outperformed international cohorts with a 60.7% treatment difference, strengthening the drug's clinical efficacy profile.
The trial results provide robust clinical evidence for the efficacy of saroglitazar in treating primary biliary cholangitis, particularly in the U.S. market, which supports the drug's potential regulatory and commercial outlook.